<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>LIB003 (Lerodalcibep) - Comprehensive Drug Profile</title>
    <style>
        * {
            margin: 0;
            padding: 0;
            box-sizing: border-box;
        }
        
        body {
            font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, sans-serif;
            background: linear-gradient(135deg, #00c9ff 0%, #92fe9d 100%);
            min-height: 100vh;
            padding: 20px;
        }
        
        .container {
            max-width: 1400px;
            margin: 0 auto;
            background: white;
            border-radius: 20px;
            box-shadow: 0 20px 60px rgba(0,0,0,0.3);
            overflow: hidden;
        }
        
        .header {
            background: linear-gradient(135deg, #00c9ff 0%, #92fe9d 100%);
            color: white;
            padding: 40px;
            position: relative;
            overflow: hidden;
        }
        
        .header::before {
            content: '';
            position: absolute;
            top: -50%;
            right: -10%;
            width: 40%;
            height: 200%;
            background: rgba(255,255,255,0.1);
            transform: rotate(45deg);
        }
        
        .drug-title {
            position: relative;
            z-index: 1;
        }
        
        .drug-name {
            font-size: 48px;
            font-weight: bold;
            margin-bottom: 10px;
            text-shadow: 2px 2px 4px rgba(0,0,0,0.2);
        }
        
        .drug-generic {
            font-size: 28px;
            opacity: 0.95;
            margin-bottom: 10px;
        }
        
        .drug-subtitle {
            font-size: 22px;
            opacity: 0.9;
            margin-bottom: 5px;
        }
        
        .drug-company {
            font-size: 20px;
            opacity: 0.85;
        }
        
        .status-badge {
            display: inline-block;
            background: rgba(255,255,255,0.25);
            padding: 10px 20px;
            border-radius: 25px;
            margin-top: 20px;
            font-weight: 600;
            backdrop-filter: blur(10px);
            font-size: 16px;
        }
        
        .nav-tabs {
            display: flex;
            background: #f8f9fa;
            border-bottom: 2px solid #e0e0e0;
            overflow-x: auto;
        }
        
        .nav-tab {
            padding: 15px 30px;
            cursor: pointer;
            border: none;
            background: transparent;
            font-size: 16px;
            font-weight: 600;
            color: #666;
            transition: all 0.3s;
            white-space: nowrap;
        }
        
        .nav-tab:hover {
            background: rgba(0, 201, 255, 0.1);
        }
        
        .nav-tab.active {
            color: #00c9ff;
            border-bottom: 3px solid #00c9ff;
            margin-bottom: -2px;
        }
        
        .content-area {
            padding: 40px;
        }
        
        .tab-content {
            display: none;
            animation: fadeIn 0.5s;
        }
        
        .tab-content.active {
            display: block;
        }
        
        @keyframes fadeIn {
            from { opacity: 0; transform: translateY(10px); }
            to { opacity: 1; transform: translateY(0); }
        }
        
        .mechanism-section {
            background: linear-gradient(135deg, #e0f7fa 0%, #b2dfdb 100%);
            border-radius: 15px;
            padding: 30px;
            margin-bottom: 30px;
        }
        
        .mechanism-title {
            font-size: 24px;
            color: #333;
            margin-bottom: 20px;
            display: flex;
            align-items: center;
        }
        
        .mechanism-icon {
            width: 40px;
            height: 40px;
            background: linear-gradient(135deg, #00c9ff 0%, #92fe9d 100%);
            border-radius: 50%;
            display: flex;
            align-items: center;
            justify-content: center;
            margin-right: 15px;
            color: white;
            font-weight: bold;
        }
        
        .mechanism-content {
            line-height: 1.8;
            color: #555;
        }
        
        .mechanism-highlight {
            background: rgba(0, 201, 255, 0.15);
            padding: 2px 6px;
            border-radius: 4px;
            font-weight: 600;
            color: #00acc1;
        }
        
        .innovation-badge {
            display: inline-block;
            background: linear-gradient(135deg, #ffd89b 0%, #19547b 100%);
            color: white;
            padding: 5px 12px;
            border-radius: 15px;
            font-size: 14px;
            font-weight: 600;
            margin-left: 10px;
        }
        
        .dosing-comparison {
            display: grid;
            grid-template-columns: repeat(auto-fit, minmax(200px, 1fr));
            gap: 20px;
            margin: 30px 0;
        }
        
        .dosing-card {
            background: white;
            border: 2px solid #e0e0e0;
            border-radius: 12px;
            padding: 20px;
            text-align: center;
            transition: all 0.3s;
            position: relative;
        }
        
        .dosing-card.highlighted {
            border-color: #00c9ff;
            background: linear-gradient(135deg, rgba(0, 201, 255, 0.05) 0%, rgba(146, 254, 157, 0.05) 100%);
            transform: scale(1.05);
            box-shadow: 0 10px 30px rgba(0, 201, 255, 0.2);
        }
        
        .dosing-card:hover {
            transform: translateY(-5px);
            box-shadow: 0 10px 30px rgba(0,0,0,0.1);
        }
        
        .dosing-frequency {
            font-size: 28px;
            font-weight: bold;
            background: linear-gradient(135deg, #00c9ff 0%, #92fe9d 100%);
            -webkit-background-clip: text;
            -webkit-text-fill-color: transparent;
            background-clip: text;
        }
        
        .dosing-product {
            font-size: 16px;
            font-weight: 600;
            color: #333;
            margin-top: 10px;
        }
        
        .dosing-detail {
            font-size: 14px;
            color: #666;
            margin-top: 5px;
        }
        
        .injections-year {
            font-size: 12px;
            color: #999;
            margin-top: 10px;
        }
        
        .timeline-container {
            margin: 30px 0;
            padding: 30px;
            background: #f8f9fa;
            border-radius: 15px;
        }
        
        .timeline-header {
            font-size: 20px;
            font-weight: bold;
            margin-bottom: 30px;
            color: #333;
        }
        
        .timeline {
            position: relative;
            padding: 20px 0;
        }
        
        .timeline-line {
            position: absolute;
            left: 50%;
            top: 0;
            bottom: 0;
            width: 3px;
            background: linear-gradient(180deg, #00c9ff 0%, #92fe9d 100%);
        }
        
        .timeline-item {
            position: relative;
            margin-bottom: 40px;
            display: flex;
            align-items: center;
        }
        
        .timeline-item:nth-child(odd) {
            flex-direction: row-reverse;
        }
        
        .timeline-content {
            width: 45%;
            background: white;
            padding: 20px;
            border-radius: 10px;
            box-shadow: 0 5px 20px rgba(0,0,0,0.1);
            position: relative;
            transition: all 0.3s;
            cursor: pointer;
        }
        
        .timeline-content:hover {
            transform: scale(1.02);
            box-shadow: 0 10px 30px rgba(0,0,0,0.15);
        }
        
        .timeline-dot {
            position: absolute;
            left: 50%;
            transform: translateX(-50%);
            width: 20px;
            height: 20px;
            background: #00c9ff;
            border: 4px solid white;
            border-radius: 50%;
            box-shadow: 0 2px 10px rgba(0,0,0,0.2);
            z-index: 1;
        }
        
        .timeline-date {
            font-weight: bold;
            color: #00c9ff;
            margin-bottom: 5px;
        }
        
        .timeline-title {
            font-size: 16px;
            font-weight: 600;
            margin-bottom: 5px;
        }
        
        .timeline-description {
            font-size: 14px;
            color: #666;
            line-height: 1.5;
        }
        
        .timeline-details {
            display: none;
            margin-top: 15px;
            padding-top: 15px;
            border-top: 1px solid #e0e0e0;
            font-size: 13px;
            color: #555;
        }
        
        .timeline-content:hover .timeline-details {
            display: block;
        }
        
        .trials-table {
            width: 100%;
            border-collapse: collapse;
            margin: 20px 0;
            background: white;
            border-radius: 10px;
            overflow: hidden;
            box-shadow: 0 5px 20px rgba(0,0,0,0.1);
        }
        
        .trials-table thead {
            background: linear-gradient(135deg, #00c9ff 0%, #92fe9d 100%);
            color: white;
        }
        
        .trials-table th {
            padding: 15px;
            text-align: left;
            font-weight: 600;
        }
        
        .trials-table td {
            padding: 15px;
            border-bottom: 1px solid #e0e0e0;
        }
        
        .trials-table tbody tr:hover {
            background: #f8f9fa;
        }
        
        .trial-phase {
            display: inline-block;
            padding: 4px 10px;
            border-radius: 20px;
            font-size: 12px;
            font-weight: 600;
        }
        
        .phase-2 { background: #e1f5fe; color: #0277bd; }
        .phase-3 { background: #e8f5e9; color: #2e7d32; }
        
        .efficacy-chart {
            background: white;
            border-radius: 15px;
            padding: 30px;
            margin: 20px 0;
            box-shadow: 0 5px 20px rgba(0,0,0,0.1);
        }
        
        .chart-title {
            font-size: 20px;
            font-weight: bold;
            margin-bottom: 20px;
            color: #333;
        }
        
        .bar-chart {
            display: flex;
            align-items: flex-end;
            height: 300px;
            gap: 30px;
            padding: 20px 0;
            justify-content: center;
        }
        
        .bar-group {
            flex: 0 0 auto;
            display: flex;
            flex-direction: column;
            align-items: center;
            justify-content: flex-end;
            min-width: 100px;
        }
        
        .bar {
            width: 80px;
            background: linear-gradient(180deg, #00c9ff 0%, #92fe9d 100%);
            border-radius: 10px 10px 0 0;
            position: relative;
            transition: all 0.3s;
            cursor: pointer;
        }
        
        .bar:hover {
            transform: scaleY(1.05);
            box-shadow: 0 5px 20px rgba(0, 201, 255, 0.3);
        }
        
        .bar-value {
            position: absolute;
            top: -30px;
            left: 50%;
            transform: translateX(-50%);
            font-weight: bold;
            font-size: 18px;
            color: #00c9ff;
            white-space: nowrap;
        }
        
        .bar-label {
            margin-top: 10px;
            text-align: center;
            font-size: 14px;
            color: #666;
            max-width: 100px;
        }
        
        .comparison-bar {
            background: linear-gradient(180deg, #ff6b6b 0%, #ff8e53 100%);
        }
        
        .safety-grid {
            display: grid;
            grid-template-columns: repeat(auto-fit, minmax(200px, 1fr));
            gap: 20px;
            margin: 20px 0;
        }
        
        .safety-card {
            background: linear-gradient(135deg, #fff 0%, #f0f9ff 100%);
            border: 2px solid #e0f7fa;
            border-radius: 12px;
            padding: 20px;
            text-align: center;
            transition: all 0.3s;
        }
        
        .safety-card:hover {
            transform: translateY(-5px);
            box-shadow: 0 10px 30px rgba(0,0,0,0.1);
            border-color: #00c9ff;
        }
        
        .safety-icon {
            font-size: 36px;
            margin-bottom: 10px;
        }
        
        .safety-percentage {
            font-size: 32px;
            font-weight: bold;
            background: linear-gradient(135deg, #00c9ff 0%, #92fe9d 100%);
            -webkit-background-clip: text;
            -webkit-text-fill-color: transparent;
            background-clip: text;
        }
        
        .safety-label {
            font-size: 14px;
            color: #666;
            margin-top: 10px;
        }
        
        .commercial-section {
            background: #f8f9fa;
            border-radius: 15px;
            padding: 30px;
            margin: 20px 0;
        }
        
        .competitive-advantages {
            display: grid;
            grid-template-columns: repeat(auto-fit, minmax(250px, 1fr));
            gap: 20px;
            margin: 20px 0;
        }
        
        .advantage-card {
            background: white;
            padding: 20px;
            border-radius: 12px;
            border-left: 4px solid;
            border-image: linear-gradient(180deg, #00c9ff 0%, #92fe9d 100%) 1;
        }
        
        .advantage-title {
            font-weight: bold;
            color: #00acc1;
            margin-bottom: 10px;
        }
        
        .advantage-description {
            color: #666;
            font-size: 14px;
            line-height: 1.6;
        }
        
        .info-grid {
            display: grid;
            grid-template-columns: repeat(auto-fit, minmax(300px, 1fr));
            gap: 30px;
            margin: 30px 0;
        }
        
        .info-card {
            background: white;
            border-radius: 15px;
            padding: 25px;
            box-shadow: 0 5px 20px rgba(0,0,0,0.1);
        }
        
        .info-card-title {
            font-size: 18px;
            font-weight: bold;
            color: #333;
            margin-bottom: 15px;
            display: flex;
            align-items: center;
        }
        
        .info-icon {
            width: 30px;
            height: 30px;
            background: linear-gradient(135deg, #00c9ff 0%, #92fe9d 100%);
            border-radius: 50%;
            display: flex;
            align-items: center;
            justify-content: center;
            margin-right: 10px;
            color: white;
            font-size: 14px;
        }
        
        .info-list {
            list-style: none;
        }
        
        .info-list li {
            padding: 8px 0;
            border-bottom: 1px solid #f0f0f0;
            color: #666;
            font-size: 14px;
        }
        
        .info-list li:last-child {
            border-bottom: none;
        }
        
        .highlight-box {
            background: linear-gradient(135deg, rgba(0, 201, 255, 0.1) 0%, rgba(146, 254, 157, 0.1) 100%);
            border-left: 4px solid #00c9ff;
            padding: 20px;
            border-radius: 8px;
            margin: 20px 0;
        }
        
        .highlight-title {
            font-weight: bold;
            color: #00acc1;
            margin-bottom: 10px;
        }
        
        .highlight-content {
            color: #555;
            line-height: 1.6;
        }
        
        .pipeline-timeline {
            position: relative;
            padding: 20px 0;
            margin: 30px 0;
        }
        
        .pipeline-track {
            height: 8px;
            background: #e0e0e0;
            border-radius: 4px;
            position: relative;
        }
        
        .pipeline-progress {
            height: 100%;
            background: linear-gradient(90deg, #00c9ff 0%, #92fe9d 100%);
            border-radius: 4px;
            width: 65%;
            position: relative;
            animation: progressGrow 2s ease-out;
        }
        
        @keyframes progressGrow {
            from { width: 0; }
        }
        
        .pipeline-milestone {
            position: absolute;
            top: -40px;
            transform: translateX(-50%);
            text-align: center;
            white-space: nowrap;
        }
        
        .milestone-dot {
            width: 16px;
            height: 16px;
            background: white;
            border: 3px solid #00c9ff;
            border-radius: 50%;
            margin: 0 auto 5px;
        }
        
        .milestone-label {
            font-size: 12px;
            color: #666;
        }
        
        .fast-track-badge {
            display: inline-block;
            background: linear-gradient(135deg, #ff6b6b 0%, #ff8e53 100%);
            color: white;
            padding: 8px 16px;
            border-radius: 20px;
            font-weight: 600;
            font-size: 14px;
            margin: 10px 0;
        }
        
        @media (max-width: 768px) {
            .timeline-item {
                flex-direction: column !important;
            }
            
            .timeline-content {
                width: 90%;
                margin: 0 auto;
            }
            
            .timeline-line {
                left: 20px;
            }
            
            .timeline-dot {
                left: 20px;
            }
            
            .bar-chart {
                height: 200px;
                flex-wrap: wrap;
            }
            
            .dosing-comparison {
                grid-template-columns: 1fr;
            }
        }
    </style>
</head>
<body>
    
    <div class="container">
        <div class="header">
            <div class="drug-title">
                <div class="drug-name">LIB003</div>
                <div class="drug-generic">Lerodalcibep</div>
                <div class="drug-subtitle">Third-Generation PCSK9 Inhibitor</div>
                <div class="drug-company">LIB Therapeutics</div>
                <span class="status-badge">Phase 3 Complete ‚Ä¢ FDA Filing Expected 2024-2025</span>
            </div>
        </div>
        
        <div class="nav-tabs">
            <button class="nav-tab active" onclick="showTab('overview')">Overview</button>
            <button class="nav-tab" onclick="showTab('mechanism')">Mechanism & Dosing</button>
            <button class="nav-tab" onclick="showTab('regulatory')">Regulatory Timeline</button>
            <button class="nav-tab" onclick="showTab('clinical')">Clinical Trials</button>
            <button class="nav-tab" onclick="showTab('safety')">Safety Profile</button>
            <button class="nav-tab" onclick="showTab('commercial')">Commercial</button>
            <button class="nav-tab" onclick="showTab('pipeline')">Pipeline & Future</button>
        </div>
        
        <div class="content-area">
            <!-- Overview Tab -->
            <div id="overview" class="tab-content active">
                <div class="info-grid">
                    <div class="info-card">
                        <div class="info-card-title">
                            <div class="info-icon">üî¨</div>
                            Innovation Profile
                        </div>
                        <ul class="info-list">
                            <li>Novel adnectin-albumin fusion protein</li>
                            <li>Smaller molecule than mAbs (~1.2 mL injection)</li>
                            <li>Once-monthly dosing (12 injections/year)</li>
                            <li>No immunogenicity detected over 52 weeks</li>
                            <li>FDA Fast Track designation granted</li>
                            <li>Technology originated from BMS, optimized by LIB</li>
                        </ul>
                    </div>
                    
                    <div class="info-card">
                        <div class="info-card-title">
                            <div class="info-icon">üìä</div>
                            Clinical Performance
                        </div>
                        <ul class="info-list">
                            <li>LIBerate-HR: 56% LDL reduction at 52 weeks</li>
                            <li>Peak efficacy: Up to 70% LDL reduction</li>
                            <li>90%+ patients achieved guideline goals</li>
                            <li>Co-primary endpoints met at 24 & 52 weeks</li>
                            <li>HoFH: ~10% reduction (meaningful in this population)</li>
                            <li>Consistent efficacy in HeFH patients</li>
                        </ul>
                    </div>
                    
                    <div class="info-card">
                        <div class="info-card-title">
                            <div class="info-icon">üéØ</div>
                            Market Position
                        </div>
                        <ul class="info-list">
                            <li>Bridges gap between Q2W mAbs and biannual inclisiran</li>
                            <li>Potential for self-administration via autoinjector</li>
                            <li>Pharmacy benefit eligible (vs medical for inclisiran)</li>
                            <li>Expected pricing 20% below existing mAbs</li>
                            <li>Patent protection into late 2030s</li>
                            <li>May need partner for large-scale commercialization</li>
                        </ul>
                    </div>
                </div>
                
                <div class="dosing-comparison">
                    <div class="dosing-card">
                        <div class="dosing-frequency">Q2W</div>
                        <div class="dosing-product">Repatha/Praluent</div>
                        <div class="dosing-detail">Standard mAbs</div>
                        <div class="injections-year">26 injections/year</div>
                    </div>
                    <div class="dosing-card highlighted">
                        <div class="dosing-frequency">Monthly</div>
                        <div class="dosing-product">LIB003</div>
                        <div class="dosing-detail">Lerodalcibep</div>
                        <div class="injections-year">12 injections/year</div>
                    </div>
                    <div class="dosing-card">
                        <div class="dosing-frequency">Q4W</div>
                        <div class="dosing-product">Praluent</div>
                        <div class="dosing-detail">Optional dosing</div>
                        <div class="injections-year">12 injections/year</div>
                    </div>
                    <div class="dosing-card">
                        <div class="dosing-frequency">Biannual</div>
                        <div class="dosing-product">Inclisiran</div>
                        <div class="dosing-detail">siRNA therapy</div>
                        <div class="injections-year">2 injections/year</div>
                    </div>
                </div>
                
                <div class="highlight-box">
                    <div class="highlight-title">Key Differentiation</div>
                    <div class="highlight-content">
                        LIB003 represents a "third-generation" approach to PCSK9 inhibition, using novel adnectin technology 
                        rather than traditional antibodies. Its monthly dosing offers a sweet spot between frequent mAb injections 
                        and very infrequent inclisiran dosing, potentially improving adherence while maintaining consistent LDL control. 
                        The smaller injection volume (1.2 mL) and lack of immunogenicity over 52 weeks demonstrate the success of 
                        its engineered protein design.
                    </div>
                </div>
            </div>
            
            <!-- Mechanism & Dosing Tab -->
            <div id="mechanism" class="tab-content">
                <div class="mechanism-section">
                    <div class="mechanism-title">
                        <div class="mechanism-icon">‚öôÔ∏è</div>
                        Mechanism of Action
                        <span class="innovation-badge">Third-Generation PCSK9i</span>
                    </div>
                    <div class="mechanism-content">
                        Lerodalcibep is a <span class="mechanism-highlight">novel small binding protein</span> consisting of an 
                        <span class="mechanism-highlight">adnectin fused to human albumin</span>. Unlike traditional monoclonal antibodies:
                        <ul style="margin-top: 15px; margin-left: 20px;">
                            <li><strong>Adnectin component:</strong> A small engineered protein based on fibronectin that specifically binds PCSK9</li>
                            <li><strong>Albumin fusion:</strong> Extends half-life to enable monthly dosing</li>
                            <li><strong>Smaller size:</strong> Being smaller than mAbs allows for highly concentrated, low-volume injections</li>
                            <li><strong>Same endpoint:</strong> Prevents PCSK9 from degrading LDL receptors, increasing LDL clearance</li>
                        </ul>
                        <br>
                        The mechanism achieves <span class="mechanism-highlight">near-maximal PCSK9 suppression</span> with a single 
                        300 mg dose, resulting in up to <span class="mechanism-highlight">70% LDL reduction</span> at peak effect. 
                        The adnectin technology originated at Bristol-Myers Squibb and was optimized by LIB Therapeutics specifically 
                        for superior binding affinity and extended duration.
                    </div>
                </div>
                
                <div class="mechanism-section">
                    <div class="mechanism-title">
                        <div class="mechanism-icon">üíâ</div>
                        Dosing Specifications
                    </div>
                    <div style="display: grid; grid-template-columns: repeat(auto-fit, minmax(250px, 1fr)); gap: 20px; margin-top: 20px;">
                        <div class="dosing-card">
                            <div class="dosing-label">Dose</div>
                            <div class="dosing-value" style="font-size: 28px; color: #00acc1;">300 mg</div>
                            <div class="dosing-detail">Fixed dose, subcutaneous</div>
                        </div>
                        <div class="dosing-card">
                            <div class="dosing-label">Frequency</div>
                            <div class="dosing-value" style="font-size: 28px; color: #00acc1;">Monthly</div>
                            <div class="dosing-detail">Once every 4 weeks</div>
                        </div>
                        <div class="dosing-card">
                            <div class="dosing-label">Volume</div>
                            <div class="dosing-value" style="font-size: 28px; color: #00acc1;">1.2 mL</div>
                            <div class="dosing-detail">Comfortable injection size</div>
                        </div>
                        <div class="dosing-card">
                            <div class="dosing-label">Annual Injections</div>
                            <div class="dosing-value" style="font-size: 28px; color: #00acc1;">12</div>
                            <div class="dosing-detail">vs 26 for Q2W mAbs</div>
                        </div>
                    </div>
                </div>
                
                <div class="highlight-box">
                    <div class="highlight-title">Dosing Advantages</div>
                    <div class="highlight-content">
                        Monthly dosing maintains consistently low LDL levels with less peak-trough variation than Q2W regimens. 
                        The schedule aligns well with typical monthly physician visits for high-risk patients. The small injection 
                        volume (1.2 mL) improves patient comfort compared to larger volume injections. Prefilled syringes used in 
                        trials, with autoinjector device likely for commercial launch enabling self-administration.
                    </div>
                </div>
            </div>
            
            <!-- Regulatory Timeline Tab -->
            <div id="regulatory" class="tab-content">
                <div class="fast-track-badge">FDA Fast Track Designation Granted</div>
                
                <div class="timeline-container">
                    <div class="timeline-header">Regulatory Development Timeline</div>
                    <div class="timeline">
                        <div class="timeline-line"></div>
                        
                        <div class="timeline-item">
                            <div class="timeline-content">
                                <div class="timeline-date">Pre-2020</div>
                                <div class="timeline-title">Technology Acquisition</div>
                                <div class="timeline-description">LIB Therapeutics acquired adnectin platform from BMS</div>
                                <div class="timeline-details">
                                    Original adnectin PCSK9 inhibitor was in Phase 1 at BMS. LIB optimized the molecule 
                                    for improved binding, stability, and half-life extension via albumin fusion.
                                </div>
                            </div>
                            <div class="timeline-dot"></div>
                        </div>
                        
                        <div class="timeline-item">
                            <div class="timeline-content">
                                <div class="timeline-date">2020-2022</div>
                                <div class="timeline-title">Phase 2 Development</div>
                                <div class="timeline-description">Dose-finding and proof of concept studies</div>
                                <div class="timeline-details">
                                    Demonstrated up to 70% LDL-C reduction at peak effect. Single 300 mg dose achieved 
                                    near-maximal PCSK9 suppression. No immunogenicity concerns identified.
                                </div>
                            </div>
                            <div class="timeline-dot"></div>
                        </div>
                        
                        <div class="timeline-item">
                            <div class="timeline-content">
                                <div class="timeline-date">2023</div>
                                <div class="timeline-title">Phase 3 Trials Initiated</div>
                                <div class="timeline-description">LIBerate-HR and LIBerate-FH trials launched</div>
                                <div class="timeline-details">
                                    FDA Fast Track designation granted for HeFH and secondary prevention. 
                                    Two pivotal trials enrolling high-risk and familial hypercholesterolemia patients.
                                </div>
                            </div>
                            <div class="timeline-dot"></div>
                        </div>
                        
                        <div class="timeline-item">
                            <div class="timeline-content">
                                <div class="timeline-date">March 2024 (ACC)</div>
                                <div class="timeline-title">LIBerate-HR Results</div>
                                <div class="timeline-description">52-week data presented at ACC 2024</div>
                                <div class="timeline-details">
                                    56% LDL reduction vs placebo over 52 weeks. Co-primary endpoints met. 
                                    No safety, tolerability, or immunogenicity concerns. Over 90% achieved guideline goals.
                                </div>
                            </div>
                            <div class="timeline-dot"></div>
                        </div>
                        
                        <div class="timeline-item">
                            <div class="timeline-content">
                                <div class="timeline-date">Mid-2024</div>
                                <div class="timeline-title">Filing Preparation Announced</div>
                                <div class="timeline-description">Company announces regulatory submission plans</div>
                                <div class="timeline-details">
                                    LIB Therapeutics indicated plans to file with FDA in late 2024 or early 2025. 
                                    Partnered manufacturing secured. No CRLs or holds reported.
                                </div>
                            </div>
                            <div class="timeline-dot"></div>
                        </div>
                        
                        <div class="timeline-item">
                            <div class="timeline-content">
                                <div class="timeline-date">Late 2024/Early 2025</div>
                                <div class="timeline-title">FDA/EMA Submissions</div>
                                <div class="timeline-description">BLA filing expected</div>
                                <div class="timeline-details">
                                    Simultaneous FDA and EMA submissions planned. Fast Track designation should expedite 
                                    FDA review. Manufacturing and immunogenicity data package complete.
                                </div>
                            </div>
                            <div class="timeline-dot"></div>
                        </div>
                        
                        <div class="timeline-item">
                            <div class="timeline-content">
                                <div class="timeline-date">2025 (Projected)</div>
                                <div class="timeline-title">Potential Approval</div>
                                <div class="timeline-description">Expected regulatory decisions</div>
                                <div class="timeline-details">
                                    Approval likely based on LDL surrogate endpoint, similar to prior PCSK9 inhibitors. 
                                    Broad label expected similar to Repatha. Post-marketing outcomes trial may be required.
                                </div>
                            </div>
                            <div class="timeline-dot"></div>
                        </div>
                    </div>
                </div>
                
                <div class="highlight-box">
                    <div class="highlight-title">Regulatory Advantages</div>
                    <div class="highlight-content">
                        No regulatory holds or CRLs reported to date. FDA Fast Track designation indicates agency support for 
                        expedited review. The novel adnectin platform has prior FDA exposure from BMS's earlier work, reducing 
                        regulatory uncertainty. Strong Phase 3 data with no immunogenicity concerns over 52 weeks addresses 
                        key regulatory questions for novel protein therapeutics. LIB has secured partnered manufacturing to 
                        avoid inclisiran-type delays.
                    </div>
                </div>
            </div>
            
            <!-- Clinical Trials Tab -->
            <div id="clinical" class="tab-content">
                <table class="trials-table">
                    <thead>
                        <tr>
                            <th>Trial</th>
                            <th>Phase</th>
                            <th>Population</th>
                            <th>N</th>
                            <th>Duration</th>
                            <th>Primary Endpoint</th>
                            <th>Key Results</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td>Phase 2<br><small>2020-2022</small></td>
                            <td><span class="trial-phase phase-2">Phase 2</span></td>
                            <td>Hypercholesterolemia</td>
                            <td>~150</td>
                            <td>12 weeks</td>
                            <td>Dose-finding, LDL-C reduction</td>
                            <td>Up to 70% LDL reduction at peak<br>300 mg dose selected<br>Near-maximal PCSK9 suppression</td>
                        </tr>
                        <tr>
                            <td>LIBerate-HR<br><small>2023-2024</small></td>
                            <td><span class="trial-phase phase-3">Phase 3</span></td>
                            <td>High CV risk<br>on max therapy</td>
                            <td>922</td>
                            <td>52 weeks</td>
                            <td>% LDL-C change at 24 & 52 weeks</td>
                            <td>56% LDL reduction at 52 weeks<br>62% reduction at 24 weeks<br>>90% achieved goals<br>No immunogenicity</td>
                        </tr>
                        <tr>
                            <td>LIBerate-FH<br><small>2023-2024</small></td>
                            <td><span class="trial-phase phase-3">Phase 3</span></td>
                            <td>HeFH patients</td>
                            <td>~450</td>
                            <td>24 weeks</td>
                            <td>% LDL-C reduction</td>
                            <td>Similar efficacy to LIBerate-HR<br>>90% achieved European goals<br>Well-tolerated</td>
                        </tr>
                        <tr>
                            <td>HoFH Study<br><small>Interim data</small></td>
                            <td><span class="trial-phase phase-3">Phase 3</span></td>
                            <td>Homozygous FH</td>
                            <td>~60</td>
                            <td>24 weeks</td>
                            <td>% LDL-C reduction</td>
                            <td>~10% LDL reduction<br>(Meaningful in HoFH)<br>Similar to Repatha in HoFH</td>
                        </tr>
                    </tbody>
                </table>
                
                <div class="efficacy-chart">
                    <div class="chart-title">LDL-C Reduction Comparison</div>
                    <div class="bar-chart">
                        <div class="bar-group">
                            <div class="bar" style="height: 70%;">
                                <div class="bar-value">70%</div>
                            </div>
                            <div class="bar-label">Phase 2<br>Peak Effect</div>
                        </div>
                        <div class="bar-group">
                            <div class="bar" style="height: 62%;">
                                <div class="bar-value">62%</div>
                            </div>
                            <div class="bar-label">LIBerate-HR<br>24 weeks</div>
                        </div>
                        <div class="bar-group">
                            <div class="bar" style="height: 56%;">
                                <div class="bar-value">56%</div>
                            </div>
                            <div class="bar-label">LIBerate-HR<br>52 weeks</div>
                        </div>
                        <div class="bar-group">
                            <div class="bar comparison-bar" style="height: 60%;">
                                <div class="bar-value">~60%</div>
                            </div>
                            <div class="bar-label">Repatha<br>Typical</div>
                        </div>
                        <div class="bar-group">
                            <div class="bar comparison-bar" style="height: 50%;">
                                <div class="bar-value">~50%</div>
                            </div>
                            <div class="bar-label">Inclisiran<br>Typical</div>
                        </div>
                    </div>
                </div>
                
                <div class="efficacy-chart">
                    <div class="chart-title">Achievement of Guideline Goals</div>
                    <div class="bar-chart">
                        <div class="bar-group">
                            <div class="bar" style="height: 90%; background: linear-gradient(180deg, #4caf50 0%, #2e7d32 100%);">
                                <div class="bar-value">>90%</div>
                            </div>
                            <div class="bar-label">LIB003<br>Achieved Goals</div>
                        </div>
                        <div class="bar-group">
                            <div class="bar" style="height: 120%; background: linear-gradient(180deg, #2196f3 0%, #1565c0 100%);">
                                <div class="bar-value">~120 mg/dL</div>
                            </div>
                            <div class="bar-label">Baseline<br>LDL-C</div>
                        </div>
                        <div class="bar-group">
                            <div class="bar" style="height: 60%; background: linear-gradient(180deg, #4caf50 0%, #2e7d32 100%);">
                                <div class="bar-value">~60 mg/dL</div>
                            </div>
                            <div class="bar-label">On-Treatment<br>LDL-C</div>
                        </div>
                        <div class="bar-group">
                            <div class="bar" style="height: 130%; background: linear-gradient(180deg, #ff6b6b 0%, #d32f2f 100%);">
                                <div class="bar-value">~130 mg/dL</div>
                            </div>
                            <div class="bar-label">Placebo<br>LDL-C</div>
                        </div>
                    </div>
                </div>
                
                <div class="highlight-box">
                    <div class="highlight-title">Clinical Outcomes Perspective</div>
                    <div class="highlight-content">
                        While no cardiovascular outcomes trial has been completed, the consistent 56-62% LDL reduction 
                        places lerodalcibep in the same efficacy range as approved PCSK9 inhibitors with proven CV benefit. 
                        The 52-week durability data is particularly strong. LIB Therapeutics may need a partner to fund 
                        a large outcomes trial, but approval will likely proceed based on LDL surrogate endpoint. 
                        The HoFH data (~10% reduction) provides a potential niche indication in this ultra-rare population.
                    </div>
                </div>
            </div>
            
            <!-- Safety Tab -->
            <div id="safety" class="tab-content">
                <div class="safety-grid">
                    <div class="safety-card">
                        <div class="safety-icon">‚úÖ</div>
                        <div class="safety-percentage">0%</div>
                        <div class="safety-label">Immunogenicity<br>Over 52 Weeks</div>
                    </div>
                    <div class="safety-card">
                        <div class="safety-icon">üî¨</div>
                        <div class="safety-percentage">Similar</div>
                        <div class="safety-label">AE Rate<br>vs Placebo</div>
                    </div>
                    <div class="safety-card">
                        <div class="safety-icon">üíä</div>
                        <div class="safety-percentage">0</div>
                        <div class="safety-label">Treatment-Related<br>Serious AEs</div>
                    </div>
                    <div class="safety-card">
                        <div class="safety-icon">üß¨</div>
                        <div class="safety-percentage">None</div>
                        <div class="safety-label">Liver/CK<br>Elevations</div>
                    </div>
                    <div class="safety-card">
                        <div class="safety-icon">üß†</div>
                        <div class="safety-percentage">None</div>
                        <div class="safety-label">Neurocognitive<br>Effects</div>
                    </div>
                    <div class="safety-card">
                        <div class="safety-icon">üíâ</div>
                        <div class="safety-percentage">Low</div>
                        <div class="safety-label">Injection Site<br>Reactions</div>
                    </div>
                </div>
                
                <div class="info-grid">
                    <div class="info-card">
                        <div class="info-card-title">
                            <div class="info-icon">‚úì</div>
                            Common Adverse Events
                        </div>
                        <ul class="info-list">
                            <li>Influenza-like symptoms (~5%)</li>
                            <li>Nasopharyngitis (~5%)</li>
                            <li>Similar rates to placebo</li>
                            <li>Mild injection site reactions (rare)</li>
                            <li>No pattern of concerning AEs</li>
                        </ul>
                    </div>
                    
                    <div class="info-card">
                        <div class="info-card-title">
                            <div class="info-icon">üõ°Ô∏è</div>
                            Key Safety Findings
                        </div>
                        <ul class="info-list">
                            <li>No neutralizing antibodies detected</li>
                            <li>No safety or tolerability concerns vs placebo</li>
                            <li>No liver enzyme elevations</li>
                            <li>No creatine kinase elevations</li>
                            <li>No cognitive impairment reported</li>
                            <li>Clean profile over 52 weeks</li>
                        </ul>
                    </div>
                    
                    <div class="info-card">
                        <div class="info-card-title">
                            <div class="info-icon">üîç</div>
                            Theoretical Considerations
                        </div>
                        <ul class="info-list">
                            <li>Adnectin scaffold highly specific to PCSK9</li>
                            <li>No off-target binding observed</li>
                            <li>Smaller size may reduce injection site inflammation</li>
                            <li>Monthly dosing reduces injection fatigue</li>
                            <li>Protein-based, no CYP interactions</li>
                            <li>Extracellular action limits organ toxicity</li>
                        </ul>
                    </div>
                </div>
                
                <div class="highlight-box">
                    <div class="highlight-title">Safety Profile Summary</div>
                    <div class="highlight-content">
                        The complete absence of immunogenicity over 52 weeks is particularly impressive for a novel engineered 
                        protein therapeutic, validating the adnectin-albumin fusion design. Safety profile essentially mirrors 
                        placebo aside from expected mild injection reactions and common viral symptoms. The lack of any 
                        treatment-related serious adverse events, liver/muscle effects, or neurocognitive signals positions 
                        lerodalcibep's safety on par with or slightly better than first-generation mAbs. Post-market surveillance 
                        will monitor for rare events in larger populations.
                    </div>
                </div>
            </div>
            
            <!-- Commercial Tab -->
            <div id="commercial" class="tab-content">
                <div class="commercial-section">
                    <div class="competitive-advantages">
                        <div class="advantage-card">
                            <div class="advantage-title">Dosing Convenience</div>
                            <div class="advantage-description">
                                Monthly dosing offers sweet spot between Q2W mAbs and biannual inclisiran. 
                                12 injections/year vs 26 for standard mAbs.
                            </div>
                        </div>
                        <div class="advantage-card">
                            <div class="advantage-title">Distribution Flexibility</div>
                            <div class="advantage-description">
                                Can be distributed through specialty pharmacy (pharmacy benefit) avoiding 
                                buy-and-bill complexities that challenged inclisiran's US launch.
                            </div>
                        </div>
                        <div class="advantage-card">
                            <div class="advantage-title">Pricing Strategy</div>
                            <div class="advantage-description">
                                Expected to price ~20% below existing mAbs to drive adoption as new entrant. 
                                May trigger formulary preferences if cost-effective.
                            </div>
                        </div>
                        <div class="advantage-card">
                            <div class="advantage-title">Small Volume</div>
                            <div class="advantage-description">
                                1.2 mL injection volume more comfortable than larger injections. 
                                Autoinjector device planned for self-administration.
                            </div>
                        </div>
                    </div>
                </div>
                
                <div class="info-grid">
                    <div class="info-card">
                        <div class="info-card-title">
                            <div class="info-icon">üí∞</div>
                            Payer Considerations
                        </div>
                        <ul class="info-list">
                            <li>Initially require same PA justification as other PCSK9i</li>
                            <li>Potential formulary preference if priced lower</li>
                            <li>Pharmacy benefit simplifies access vs medical</li>
                            <li>Monthly schedule aligns with specialty pharmacy</li>
                            <li>Class outcomes data supports coverage</li>
                        </ul>
                    </div>
                    
                    <div class="info-card">
                        <div class="info-card-title">
                            <div class="info-icon">üè•</div>
                            Target Markets
                        </div>
                        <ul class="info-list">
                            <li>Statin-intolerant patients (50-60% LDL reduction)</li>
                            <li>Patients preferring monthly vs Q2W schedule</li>
                            <li>Those who can't adhere to biweekly injections</li>
                            <li>HoFH patients (niche ultra-rare indication)</li>
                            <li>VA and integrated health systems</li>
                        </ul>
                    </div>
                    
                    <div class="info-card">
                        <div class="info-card-title">
                            <div class="info-icon">üåç</div>
                            Global Strategy
                        </div>
                        <ul class="info-list">
                            <li>Simultaneous US/EU filing planned</li>
                            <li>May need big pharma partner for scale</li>
                            <li>Europe pricing critical vs inclisiran (~‚Ç¨2000/dose)</li>
                            <li>NHS unlikely to switch from inclisiran deal</li>
                            <li>Focus on markets without existing contracts</li>
                        </ul>
                    </div>
                </div>
                
                <div class="highlight-box">
                    <div class="highlight-title">Commercial Outlook</div>
                    <div class="highlight-content">
                        LIB003 enters market as an "intermediate option" - more convenient than Q2W mAbs but more frequent 
                        than inclisiran. Success depends on pricing strategy and distribution efficiency. Avoiding buy-and-bill 
                        by using specialty pharmacy channels could accelerate uptake. The 2025-2026 launch window gives 
                        opportunity to establish market share before oral PCSK9 inhibitors arrive. Small company status 
                        may necessitate partnership for full commercial potential. Best positioned for statin-intolerant 
                        patients and those seeking monthly regimen alignment with other chronic therapies.
                    </div>
                </div>
            </div>
            
            <!-- Pipeline Tab -->
            <div id="pipeline" class="tab-content">
                <div class="pipeline-timeline">
                    <div class="pipeline-track">
                        <div class="pipeline-progress"></div>
                    </div>
                    <div class="pipeline-milestone" style="left: 0;">
                        <div class="milestone-dot"></div>
                        <div class="milestone-label">Technology<br>Acquisition</div>
                    </div>
                    <div class="pipeline-milestone" style="left: 25%;">
                        <div class="milestone-dot"></div>
                        <div class="milestone-label">Phase 2</div>
                    </div>
                    <div class="pipeline-milestone" style="left: 50%;">
                        <div class="milestone-dot"></div>
                        <div class="milestone-label">Phase 3</div>
                    </div>
                    <div class="pipeline-milestone" style="left: 65%;">
                        <div class="milestone-dot" style="background: #00c9ff;"></div>
                        <div class="milestone-label"><strong>Filing (Current)</strong></div>
                    </div>
                    <div class="pipeline-milestone" style="left: 75%;">
                        <div class="milestone-dot"></div>
                        <div class="milestone-label">Approval<br>(2025)</div>
                    </div>
                    <div class="pipeline-milestone" style="left: 100%;">
                        <div class="milestone-dot"></div>
                        <div class="milestone-label">Biosimilar<br>Competition<br>(~2028)</div>
                    </div>
                </div>
                
                <div class="info-grid">
                    <div class="info-card">
                        <div class="info-card-title">
                            <div class="info-icon">üîÆ</div>
                            Near-Term Outlook (2025-2027)
                        </div>
                        <ul class="info-list">
                            <li>FDA approval expected 2025</li>
                            <li>Critical window before oral PCSK9i dominance</li>
                            <li>Build market share with aggressive pricing</li>
                            <li>Potential head-to-head vs Repatha study</li>
                            <li>Partnership likely for outcomes trial</li>
                            <li>HoFH indication provides differentiation</li>
                        </ul>
                    </div>
                    
                    <div class="info-card">
                        <div class="info-card-title">
                            <div class="info-icon">‚öîÔ∏è</div>
                            Competitive Threats
                        </div>
                        <ul class="info-list">
                            <li>Oral PCSK9i (MK-0616, AZD0780) by 2027</li>
                            <li>Biosimilar mAbs expected ~2028</li>
                            <li>Gene therapy eventual long-term threat</li>
                            <li>Inclisiran gaining traction with health systems</li>
                            <li>Price pressure from multiple entrants</li>
                        </ul>
                    </div>
                    
                    <div class="info-card">
                        <div class="info-card-title">
                            <div class="info-icon">üöÄ</div>
                            Innovation Potential
                        </div>
                        <ul class="info-list">
                            <li>Longer-acting depot formulation possible</li>
                            <li>Combination with inclisiran for extreme cases</li>
                            <li>Platform applicable to other targets</li>
                            <li>Autoinjector device for home use</li>
                            <li>Patent protection to late 2030s</li>
                        </ul>
                    </div>
                </div>
                
                <div class="highlight-box">
                    <div class="highlight-title">Long-Term Sustainability</div>
                    <div class="highlight-content">
                        LIB003 represents an important interim competitor that raises the bar for convenience vs Q2W mAbs. 
                        Its window of opportunity is 2025-2028, before oral PCSK9 inhibitors and biosimilars reshape the market. 
                        Long-term survival depends on demonstrating clinical advantages (adherence, outcomes) or finding niches 
                        (HoFH, combination therapy). The adnectin platform technology could be applied to other therapeutic 
                        targets, providing pipeline beyond PCSK9. Monthly injections may retain relevance for patients preferring 
                        injections over daily pills or those with adherence challenges. Critical to establish strong market 
                        position quickly before landscape shifts dramatically.
                    </div>
                </div>
            </div>
        </div>
    </div>
    
    <script>
        function showTab(tabName) {
            // Hide all tabs
            const tabs = document.querySelectorAll('.tab-content');
            tabs.forEach(tab => tab.classList.remove('active'));
            
            // Remove active class from all nav tabs
            const navTabs = document.querySelectorAll('.nav-tab');
            navTabs.forEach(tab => tab.classList.remove('active'));
            
            // Show selected tab
            document.getElementById(tabName).classList.add('active');
            
            // Add active class to clicked nav tab
            event.target.classList.add('active');
        }
    </script>
</body>
</html>